Comparative Pharmacology
Head-to-head clinical analysis: CASODEX versus FLUTAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CASODEX versus FLUTAMIDE.
CASODEX vs FLUTAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal antiandrogen that competitively inhibits the action of androgens by binding to cytosolic androgen receptors in target tissues, thereby blocking androgen-mediated gene expression and tumor growth. Does not suppress androgen production.
Nonsteroidal antiandrogen; competitively inhibits androgen binding to androgen receptors, thereby blocking androgen action in target tissues.
50 mg orally once daily
250 mg orally every 8 hours. Total daily dose: 750 mg.
None Documented
None Documented
Terminal elimination half-life: 5-7 days (steady-state achieved in ~4 weeks); Long half-life due to high protein binding and slow tissue redistribution
Clinical Note
moderateFlutamide + Digoxin
"Flutamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFlutamide + Digitoxin
"Flutamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFlutamide + Deslanoside
"Flutamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFlutamide + Acetyldigitoxin
"Flutamide may decrease the cardiotoxic activities of Acetyldigitoxin."
Flutamide has an initial half-life of about 5–6 hours; its active metabolite, 2-hydroxyflutamide, has a terminal elimination half-life of 8–10 hours, supporting twice-daily dosing for steady-state concentrations.
Renal: <1% as unchanged drug; Fecal: ~83% as metabolites (mostly glucuronide conjugates); Biliary: significant as metabolites; Total clearance: 0.42 mL/min/kg
Primarily renal (approximately 98% of absorbed dose as metabolites, with ~4.5% as the active metabolite 2-hydroxyflutamide); less than 1% excreted unchanged; biliary/fecal elimination is minimal (<1%).
Category C
Category D/X
Antiandrogen
Antiandrogen